A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.
| Website | http://www.intervacc.se |
| Revenue | $5.7 million |
| Employees | 17 (13 on RocketReach) |
| Address | Västertorpsvägen 135, Stockholm, Stockholm County, SE |
| Phone | +46 70 730 56 70 |
| Fax | +61 8 1201 0640 |
| Industry | Pharmaceutical Manufacturing, Organizations General, Organizations |
| Keywords | Animal Vaccines, Disease Prevention, Veterinary Vaccines, Therapeutic Vaccines, Vaccine Development, Livestock Vaccines, Animal Healthcare, Vaccine Technology, Veterinary Medicine, Animal Immunology, Vaccine Research, Biotechnology, Pharmaceutical |
| Competitors | Merck Animal Health, Boehringer Ingelheim, Zoetis, Elanco, Virbac, Ceva Santé Animale, Phibro Animal Health, Vetoquinol Global, Vetstream Ltd +38 more (view full list) |
| SIC | SIC Code 51 Companies, SIC Code 512 Companies |
| NAICS | NAICS Code 424 Companies, NAICS Code 42 Companies, NAICS Code 4242 Companies, NAICS Code 42421 Companies |
Looking for a particular Intervacc AB employee's phone or email?
Intervacc AB Questions
The Intervacc AB annual revenue was $5.7 million in 2026.
Jonas Sohlman is the CEO of Intervacc AB.
13 people are employed at Intervacc AB.
Intervacc AB is based in Stockholm, Stockholm County.
The NAICS codes for Intervacc AB are [424, 42, 4242, 42421].
The SIC codes for Intervacc AB are [51, 512].
Top Intervacc AB Employees
-
Jonas Sohlman
Chief Executive Officer at Intervacc AB
Stockholm, SE24 -
Andrew Waller
Chief Scientific Officer at Intervacc AB
Harrogate, GB21 -
Magnus Busch
Consultant at Intervacc AB
Antwerp, BE1 -
11
-
Katja Lindholm
PV and MI Officer dQPPV at Intervacc AB
Stockholm, SE1
